| Literature DB >> 30630376 |
Alka M Kanaya1, Eric Vittinghoff1, Feng Lin1, Namratha R Kandula2, David Herrington3, Kiang Liu2, Michael Blaha4, Matthew J Budoff5.
Abstract
Background South Asians have a relatively high prevalence of coronary artery calcium ( CAC ) compared with other race/ethnic groups. We determined CAC incidence and progression among South Asians, and compared them with 4 race/ethnic groups. Methods and Results Data from the MASALA (Mediators of Atherosclerosis in South Asians Living in America) study were used to calculate CAC incidence and progression rates and any CAC change. Data from the MESA (Multi-Ethnic Study of Atherosclerosis) were used to compare the CAC incidence and progression rates. A total of 698 South Asians had repeat CAC measurements after 4.8±0.8 years. Among those with no CAC at baseline, the age-adjusted CAC incidence was 8.8% (95% CI, 6.8-10.8%) in men and 3.6% (2.5-4.8%) in women. The median annual CAC progression was 26 (interquartile range, 11-62) for men and 13 (interquartile range, 4-34) for women. Compared with MESA , age-adjusted CAC incidence was similar in South Asian men compared with white, black, and Latino men, but significantly higher than Chinese men (11.1% versus 5.7%, P=0.008). After adjusting for age, diabetes mellitus, hypertension, and statin medication use, Chinese, black, and Latino men had significantly less CAC change compared with South Asian men, but there were no differences between South Asian and white men. There was no difference in CAC incidence or progression between South Asian women and women in MESA . Conclusions South Asian men had greater CAC change than Chinese, black, and Latino men but similar change to that of whites after adjusting for traditional risk factors.Entities:
Keywords: coronary artery calcium; epidemiology; ethnic differences
Mesh:
Substances:
Year: 2019 PMID: 30630376 PMCID: PMC6497354 DOI: 10.1161/JAHA.118.011053
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Characteristics of the MASALA Study Participants by Sex at Examination 1 and Examination 2*
| Men (n=395) | Women (n=303) | |||||
|---|---|---|---|---|---|---|
| Examination 1 | Examination 2 |
| Examination 1 | Examination 2 |
| |
| Age, y | 56±10 | 60±10 | <0.001 | 54±8 | 58±9 | <0.001 |
| Current smoker | 21 (5) | 18 (5) | 0.62 | 3 (1) | 2 (1) | 0.65 |
| Alcohol use ≥1 drink/d | 188 (48) | 195 (49) | 0.62 | 63 (21) | 69 (23) | 0.55 |
| Exercise, MET‐min/wk | 1050 (420–1965) | 1260 (472–2190) | 0.05 | 840 (315–1875) | 1155 (465–2100) | 0.01 |
| BMI, kg/m2 | 25.8±3.7 | 26.3±3.7 | 0.001 | 25.8±4.2 | 26.7±4.3 | 0.001 |
| Waist circumference, cm | 95.8±9.4 | 97.2±9.6 | <0.001 | 88.5±9.8 | 91.4±10.8 | <0.001 |
| Systolic blood pressure, mm Hg | 126±14 | 130±16 | <0.001 | 122±17 | 125±18 | <0.001 |
| Diastolic blood pressure, mm Hg | 76±9 | 77±9 | <0.001 | 69±10 | 73±9 | <0.001 |
| Hypertension | 168 (43) | 221 (56) | <0.001 | 101 (33) | 117 (39) | 0.18 |
| Diabetes mellitus | 106 (27) | 128 (32) | 0.10 | 56 (19) | 66 (22) | 0.32 |
| LDL‐cholesterol, mmol/L | 2.8±0.8 | 2.8±0.9 | 0.96 | 2.9±0.8 | 3.0±0.8 | 0.96 |
| HDL‐cholesterol, mmol/L | 1.1 (1.0–1.3) | 1.2 (1.0–1.3) | 0.42 | 1.4 (1.2–1.7) | 1.5 (1.2–1.7) | 0.41 |
| Triglycerides, mmol/L | 1.4 (1.0–1.9) | 1.3 (1.0–1.8) | 0.04 | 1.2 (0.9–1.6) | 1.3 (1.0–1.7) | 0.11 |
| Fasting glucose, mmol/L | 5.9±1.4 | 6.3±1.4 | <0.001 | 5.4±1.1 | 5.7±1.0 | <0.001 |
| Statin medication use | 121 (31%) | 148 (37%) | 0.04 | 61 (20%) | 67 (27%) | 0.55 |
| CAC score | ||||||
| Zero | 174 (44.1) | 102 (25.8) | <0.001 | 234 (77.2) | 197 (65.0) | <0.001 |
| 1–100 | 115 (29.1) | 132 (33.4) | 46 (15.2) | 67 (22.1) | ||
| 101–400 | 63 (16.0) | 77 (19.5) | 14 (4.6) | 23 (7.6) | ||
| >400 | 43 (10.9) | 87 (21.3) | 9 (3.0) | 16 (5.3) | ||
BMI indicates body mass index; CAC, coronary artery calcium; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; MET, metabolic equivalent task.
Values are presented as n (%), or mean±SD, or median (interquartile range), as appropriate; P values compare examination 1 and examination 2 values within each sex.
Hypertension was defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or use of any antihypertension medication.
Diabetes mellitus was defined as fasting glucose ≥126 mg/dL and/or use of an antidiabetes mellitus medication.
Baseline Factors Associated With Any CAC Change (Modeled as Log Change in CAC+1) Among MASALA Participants, Ages 40 to 84 Years at Baseline
| Baseline Characteristic | Univariate Model (n=698) |
| Multivariable Model (n=694) |
|
|---|---|---|---|---|
| Fold Change (95% CI) | Fold Change (95% CI) | |||
| Male sex | 6.80 (4.92–9.38) | <0.001 | 4.45 (3.19–6.22) | <0.001 |
| Age, per SD (y) | 2.90 (2.48–3.39) | <0.001 | 2.17 (1.88–2.51) | <0.001 |
| Years lived in the United States | ||||
| Tertile 1 | 1.00 | |||
| Tertile 2 | 1.57 (1.04–2.37) | 0.03 | ||
| Tertile 3 | 4.50 (2.93–6.90) | <0.001 | ||
| Education, ≤High school | 1.00 | |||
| <Bachelor's degree | 0.81 (0.28–2.36) | 0.70 | ||
| =Bachelor's degree | 1.01 (0.46–2.24) | 0.98 | ||
| >Bachelor's degree | 1.13 (0.53–2.39) | 0.76 | ||
| Family income, <$40 000 | 1.00 | |||
| $40 000–75 000 | 0.66 (0.31–1.40) | 0.28 | ||
| $75 001–100 000 | 0.56 (0.25–1.27) | 0.17 | ||
| >$100 000 | 0.46 (0.25–0.86) | 0.01 | ||
| Current smoker | 4.08 (1.57–10.59) | 0.004 | 2.35 (1.10–5.02) | 0.03 |
| Alcohol consumption, none | 1.00 | |||
| 1– to 7 drinks/wk | 1.97 (1.35–2.88) | <0.001 | ||
| >7 drinks/wk | 3.04 (1.36–6.76) | 0.007 | ||
| Exercise, per SD (MET‐min/wk) | 1.07 (0.90–1.28) | 0.42 | ||
| Total caloric intake, per SD (kcal/d) | 1.01 (0.85–1.21) | 0.88 | 0.91 (0.79–1.05) | 0.18 |
| Family history of heart disease | 1.44 (1.01–2.04) | 0.04 | 1.22 (0.92–1.61) | 0.17 |
| Statin medication use | 4.58 (3.13–6.71) | <0.001 | 1.71 (1.22–2.41) | 0.002 |
| Hypertension medication use | 6.70 (4.67–9.60) | <0.001 | 2.27 (1.61–3.21) | <0.001 |
| Systolic blood pressure, <120 mm Hg | 1.00 | |||
| 120–140 | 3.16 (2.19–4.55) | <0.001 | ||
| >140 | 4.60 (2.78–7.64) | <0.001 | ||
| Diastolic blood pressure, <80 mm Hg | 1.00 | |||
| 80–90 | 2.07 (1.34–3.19) | 0.001 | ||
| >90 | 1.13 (0.48–2.68) | 0.78 | ||
| Glucose tolerance, normal | 1.00 | 1.00 | ||
| Prediabetes | 1.73 (1.17–2.56) | 0.006 | 1.07 (0.78–1.48) | 0.68 |
| Diabetes mellitus | 4.65 (3.00–7.20) | <0.001 | 1.46 (0.99–2.15) | 0.06 |
| BMI, per SD (kg/m2) | 1.14 (0.95–1.35) | 0.15 | ||
| Waist‐to‐hip ratio, per SD | 2.18 (1.85–2.58) | <0.001 | 1.07 (0.90–1.26) | 0.44 |
| Visceral fat area, cm2 | ||||
| Tertile 1 | 1.00 | |||
| Tertile 2 | 1.40 (0.92–2.12) | 0.12 | ||
| Tertile 3 | 3.85 (2.54–5.84) | <0.001 | ||
| Hepatic fat attenuation, HU | ||||
| Tertile 1 | 1.00 | |||
| Tertile 2 | 0.78 (0.51–1.19) | 0.24 | ||
| Tertile 3 | 0.39 (0.26–0.60) | <0.001 | ||
| Pericardial fat volume, cm3 | ||||
| Tertile 1 | 1.00 | |||
| Tertile 2 | 2.30 (1.53–3.47) | <0.001 | ||
| Tertile 3 | 5.34 (3.54–8.05) | <0.001 | ||
| Total cholesterol, mmol/L | ||||
| <4.14 | 1.00 | |||
| 4.14–4.91 | 0.40 (0.25–0.64) | <0.001 | ||
| >4.9 | 0.34 (0.22–0.53) | <0.001 | ||
| HDL‐cholesterol, mmol/L | ||||
| >1.68 | 1.00 | |||
| 0.90–1.68 | 1.39 (0.81–2.39) | 0.23 | ||
| <90 | 3.05 (1.48–6.28) | 0.003 | ||
| Log triglycerides, mmol/L | 1.13 (0.77–1.65) | 0.54 | ||
| Lp(a), mmol/L | ||||
| ≤0.50 | 1.00 | |||
| 0.50–1.78 | 0.87 (0.57–1.32) | 0.52 | ||
| >1.78 | 0.99 (0.64–1.52) | 0.95 | ||
| Log hsCRP, μg/mL | 0.87 (0.73–1.03) | 0.10 | ||
| Fasting insulin, per SD (pmol/L) | 1.25 (1.04–1.49) | 0.02 | ||
BMI indicates body mass index; CAC, coronary artery calcium; HDL, high‐density lipoprotein; hsCRP, high sensitivity C‐reactive protein; HU, Hounsfield units; LDL, low‐density lipoprotein; Lp(a), MASALA, Mediators of Atherosclerosis in South Asians Living in America; MET, metabolic equivalent task.
With log of CAC change as the outcome in the linear model, the exponentiated regression coefficient for each predictor is interpretable as the fold‐change in the expected value of the outcome for a 1‐unit increase in the predictor.
Defined using fasting plasma glucose (FPG) and 2‐h postchallenge glucose (2 h PG); diabetes if FPG ≥7.0 mmol/L or 2 h PG ≥11.1 mmol/L or use of a diabetes mellitus medication; prediabetes if FPG 5.6–6.9 mmol/L or 2 h PG 7.8–11.0 mmol/L; normal if FPG <5.6 mmol/L and 2 h PG <7.8 mmol/L.
Figure 1Any incident CAC (per 100 person‐years) among those with no evidence of CAC at baseline, comparing MASALA South Asians with the 4 race/ethnic groups in MESA, adjusted by age. CAC indicates coronary artery calcium; MASALA, Mediators of Atherosclerosis in South Asians Living in America; MESA, Multi‐Ethnic Study of Atherosclerosis.
Annualized CAC Progression Among Those With Any Detectable CAC at Baseline, Comparing South Asians in MASALA to the 4 MESA Race/Ethnic Groups Separately by Sex, Adjusted by Age
| CAC Progression | South Asian | White | Black | Latino | Chinese American |
|---|---|---|---|---|---|
| Men: | n=210 | n=771 | n=348 | n=336 | n=199 |
| <0 | 3.0 (0.8–5.2) | 12.5 (10.2–14.8) | 13.1 (9.6–16.6) | 13.5 (9.9–17.1) | 9.9 (5.8–14.0) |
| 0 to 9 | 16.3 (11.7–21.0) | 21.1 (18.3–23.9) | 22.1 (17.8–26.4) | 26.5 (21.8–31.1) | 21.2 (15.6–26.8) |
| 10 to 99 | 60.8 (54.1–67.6) | 49.9 (46.3–53.4) | 47.2 (42.0–52.4) | 44.6 (39.3–49.9) | 59.1 (52.3–65.9) |
| 100 to 199 | 13.2 (8.2–18.2) | 10.9 (8.7–13.1) | 10.5 (7.3–13.7) | 9.8 (6.6–13.0) | 6.2 (2.8–9.6) |
| 200+ | 6.7 (2.7–10.6) | 5.6 (4.0–7.2) | 7.1 (4.4–9.8) | 5.6 (3.1–8.1) | 3.6 (1.0–6.3) |
|
| Ref. | 0.001 | <0.001 | <0.001 | 0.004 |
| Men (not taking statins) | n=107 | n=495 | n=253 | n=252 | n=152 |
| <0 | 5.4 (1.2–9.6) | 12.9 (10.0–15.9) | 15.5 (11.0–19.9) | 15.0 (10.6–19.4) | 12.5 (7.2–17.7) |
| 0 to 9 | 14.9 (8.7–21.2) | 24.3 (20.5–28.0) | 22.3 (17.3–27.4) | 28.7 (23.2–34.2) | 24.4 (17.7–31.1) |
| 10 to 99 | 61.2 (51.7–70.8) | 50.6 (46.2–55.0) | 49.0 (42.8–55.1) | 44.8 (38.7–51.0) | 56.0 (48.1–63.8) |
| 100 to 199 | 11.5 (4.9–18.2) | 8.0 (5.7–10.3) | 8.6 (5.2–12.1) | 8.7 (5.2–12.1) | 5.2 (1.7–8.8) |
| 200+ | 6.9 (1.1–12.6) | 4.2 (2.5–5.9) | 4.6 (2.1–7.2) | 2.7 (0.8–4.7) | 2.0 (0.0–4.1) |
|
| Ref. | 0.02 | 0.02 | 0.001 | 0.01 |
| Women: | n=67 | n=507 | n=302 | n=228 | n=142 |
| <0 | 7.6 (1.2–14.0) | 13.1 (10.2–16.1) | 13.7 (9.8–17.6) | 16.8 (11.9–21.7) | 17.9 (11.6–24.2) |
| 0–9 | 32.2 (21.4–43.0) | 29.9 (25.9–33.9) | 24.2 (19.4–29.1) | 30.6 (24.6–36.6) | 29.6 (22.2–37.1) |
| 10–99 | 54.4 (42.6–66.4) | 46.7 (42.3–51.0) | 52.8 (47.2–58.4) | 46.1 (39.7–52.5) | 42.1 (35.0–51.2) |
| 100–199 | 5.7 (0–11.8) | 7.7 (5.5–9.9) | 4.4 (2.1–6.6) | 5.7 (2.8–8.6) | 5.4 (1.8–9.0) |
| 200+ | 0 | 2.6 (1.3–3.9) | 4.8 (2.5–7.1) | 0.8 (0–1.9) | 4.0 (0.9–7.1) |
|
| Ref. | 0.67 | 0.57 | 0.48 | 0.39 |
CAC indicates coronary artery calcium; MASALA, Mediators of Atherosclerosis in South Asians Living in America; MESA, Multi‐Ethnic Study of Atherosclerosis.
P‐value comparing the distribution of CAC progression among each MESA race/ethnic group to South Asians.
This subgroup of men excludes those who were taking any statin medications at the follow‐up exam for each study.
Multivariable Linear Regression Model of the Effect of Race/Ethnicity on Any CAC Change (Modeled as Log CAC Change+1) Comparing South Asian Men With Men in the 4 Race/Ethnic Groups in MESA
| Fold Change (95% CI) |
| |
|---|---|---|
| Race/ethnicity: South Asian (reference) | ||
| White | 1.06 (0.82–1.36) | 0.65 |
| Black | 0.45 (0.34–0.58) | <0.001 |
| Latino | 0.61 (0.46–0.79) | <0.001 |
| Chinese American | 0.65 (0.48–0.88) | 0.005 |
| Age, y (linear) | 1.10 (1.08–1.12) | <0.001 |
| Age, y (nonlinear) | 0.97 (0.95–1.00) | 0.02 |
| Current smoker | 1.37 (1.11–1.69) | 0.004 |
| Diabetes mellitus | 2.11 (1.68–2.63) | <0.001 |
| Hypertension | 1.76 (1.51–2.06) | <0.001 |
| Statin medication use | 1.68 (1.38–2.04) | <0.001 |
CAC indicates coronary artery calcium; MESA, Multi‐Ethnic Study of Atherosclerosis.
With log of CAC change as the outcome in the linear model, the exponentiated regression coefficient for each predictor is interpretable as the fold‐change in the expected value of the outcome for a 1‐unit increase in the predictor. Fold changes are related 1 to 1 to percent changes: 1.5‐, 2‐, and 5‐fold changes are equivalent to 50%, 100%, and 400% increases.
Defined if fasting plasma glucose ≥7.0 mmol/L or use of a diabetes mellitus medication.
Defined if systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or use of an antihypertensive medication.